Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
February 14 2022 - 4:15PM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced plans to report fourth quarter
and full year 2021 financial results on Friday, February 25,
2022, before market open.
The company will not be hosting a teleconference in conjunction
with its financial results press release.
About Rubius TherapeuticsRubius
Therapeutics is a clinical-stage biopharmaceutical company
developing a new class of medicines called Red Cell Therapeutics™.
The Company’s proprietary RED PLATFORM® was designed to
biologically engineer and culture Red Cell Therapeutics™ that are
selective, potent and off-the-shelf allogeneic cellular therapies
for the potential treatment of several diseases across multiple
therapeutic areas. Rubius’ initial focus is to advance RCT™ product
candidates for the treatment of cancer and autoimmune diseases by
leveraging two distinct therapeutic modalities — potent cell-cell
interaction and tolerance induction. Rubius Therapeutics was
recently named among the 2021 Top Places to Work in Massachusetts
by the Boston Globe, and its manufacturing site was recently
named 2021 Best Places to Work in Rhode Island by
Providence Business News. For more information, visit
www.rubiustx.com, follow us on Twitter or LinkedIn or like us on
Facebook.
Contacts:InvestorsElhan Webb,
CFA, VP Investor Relationselhan.webb@rubiustx.com
MediaMarissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2023 to Apr 2024